US+1 646-781-8004
Europe+44-203-868-8738
APAC+91-744-778-0008
sales@meticulousresearch.com
Home Report
Store
Continuous Bioprocessing Market
Continuous Bioprocessing Market by Product (Filtration, Chromatography, Centrifuges, Consumables), Application (Commercial {Vaccines, Monoclonal Antibodies}, R&D), End User (Pharmaceuticals, Biotechnology, CROs), and Geography - Forecast to 2028
Report ID:MRHC - 104380 Pages: 185 Jun-2021 Formats*: PDF Category: Healthcare Delivery: 2 to 4 HoursThe Continuous Bioprocessing Market is expected to grow at a CAGR of 23.0% from 2021 to reach $429.12 million by 2028. Continuous bioprocessing involves manufacturing biopharmaceuticals where continuous unit operations are physically connected with minimal hold volume. Some of the major factors driving the growth of this market include the growing demand for biopharmaceuticals, technological developments in continuous bioprocessing, product launches in the area of continuous bioprocessing, and global initiatives supporting the adoption of biopharmaceuticals. The growing shift towards the bioprocess 4.0 industry, growing opportunities in developing countries, and rising preference for personalized medicine are expected to create significant market growth opportunities.
COVID-19 Impact Assessment
The COVID-19 pandemic has affected most industries, including the biopharma industry. Changes in the bio/pharmaceutical industry have accelerated as a response to the ongoing COVID-19 pandemic. The biopharma industry is adopting improved strategies to tackle the current pandemic, prepare for future pandemics, and minimize supply disruptions. The industry is witnessing partnerships and collaborations focused on accelerating R&D and implementing flexible, rapid, and modular production processes to speed up the products’ time to market. Such factors are projected to drive the demand for continuous bioprocessing amid the COVID-19 pandemic.
The COVID-19 pandemic has affected most industries, including the biopharma industry. Changes in the bio/pharmaceutical industry have accelerated as a response to the ongoing COVID-19 pandemic. The biopharma industry is adopting improved strategies to tackle the current pandemic, prepare for future pandemics, and minimize supply disruptions. The industry is witnessing partnerships and collaborations focused on accelerating R&D and implementing flexible, rapid, and modular production processes to speed up the products’ time to market. Such factors are projected to drive the demand for continuous bioprocessing amid the COVID-19 pandemic. With the growing number of vaccine and therapeutic candidates in the pipeline, the demand for novel manufacturing approaches, such as continuous processing, is expected to positively impact the market in the long term.
Pharma manufacturers are investing in vaccine development and production. For instance, in June 2020, the Serum Institute of India (India) announced an investment of USD 100 million in the COVID-19 vaccine being developed at Oxford University, in partnership with AstraZeneca Plc. (U.K.), to ensure equitable supply of the AZD1222 vaccine doses to India as well as other low-and-middle-income countries. In December 2020, China-based Sinovac Biotech Ltd. received an investment of USD 515 million from local firm Sino Biopharmaceutical to accelerate the production of a COVID-19 vaccine candidate. Such initiatives are expected to create favorable market opportunities.
As per the Global Vaccine Market Report released by WHO in December 2019, the annual demand for vaccines had reached 3.5 billion doses in 2018. However, with the emergence of COVID-19, this number is expected to reach 9 billion doses of different vaccine modalities by the end of 2021. This sizeable requirement is expected to generate novel approaches like continuous bioprocessing and the use of single-use technologies.
However, the global spread of COVID-19 also adversely impacted operations, sales, and delivery & supply chains. Many countries implemented national lockdowns, shelter-in-place, curfews, travel restrictions, and isolation measures delaying distributions and affecting supply chains of the necessary instruments and consumables, negatively impacting continuous bioprocessing.
Thus, apart from few supply disruptions and operational challenges during the first phase of the pandemic, the overall impact of COVID-19 is expected to be positive on the market with growing pressure from the policymakers to develop novel vaccines and therapies cost-effectively.
Click here to: Get Free Request Sample Copy of this report
Various initiatives supporting the adoption of biopharmaceuticals is projected to drive the adoption of continuous bioprocessing
The global biosimilars market is fast-growing and possesses strong economic value. Pricing for biosimilars is usually 30-50% lower than that of biologics. This cost advantage gives greater access to biosimilars, further lowering the health expenditure in many countries. As per the Center for Medical Economics and Innovation at the Pacific Research Institute (PRI), U.S., expanding the use of biosimilars to treat serious illnesses like autoimmune diseases or cancer can help reduce the out-of-pocket spending by 17% for the patient.
Between 2017-2024, it is projected that near about biologics worth USD 100 billion will go off patent, creating opportunities for the biosimilars. The U.S. FDA is expecting the review of over 66 biosimilars as 66 biologics are going off-patent between 2020 and 2025. Knowing the high potential in the biosimilars business, market players such as Mylan N.V (U.S.), Biocon Limited (India), and Aurobindo Pharma Limited (India) are investing in biosimilars. Growing developments in the space of biosimilars are further fueled by supportive initiatives across various countries worldwide.
In February 2020, the U.S. FDA transitioned to a new regulatory pathway to boost the competition between biological products. The U.S. FDA and the Federal Trade Commission (FTC) signed a joint statement regarding enhanced collaboration to support a robust marketplace for biological products like biosimilars and interchangeable products.
China and India are among the leading countries in terms of the development and commercialization of biosimilars. The Chinese government offers multiple initiatives facilitating the development and adoption of biosimilars. The Marketing Authorization Holder (MAH) pilot scheme was launched in China, allowing license holders to sell drugs in China using a contract manufacturer, driving innovations and accelerating the speed at which international companies can introduce products in China, facilitating the growth of CDMOs. Such initiatives are driving the adoption of biosimilars globally, thereby positively impacting the demand for continuous bioprocessing technologies.
Active research in the area of personalized therapies to create several opportunities for market growth
Growing advances in proteomic and genomic sciences have boosted the emergence of personalized therapies. The wave of personalized medicines has entered a mainstream clinical approach, changing the identification, classification, or treatment of diseases. The recognition for personalized medicines is growing among the policymakers, driving the innovative approaches of developing and producing personalized therapies. Continuous bioprocessing and greater accuracy through data analytics and monitoring allow for higher concentrations of next-generation biologics drug dosages, enabling more personalized and effective medicines in potentially smaller/less frequent administration and dosages.
With the pharmaceutical industry moving towards the development of personalized therapies, new manufacturing approaches are being adopted to meet the growing market demand. Advancing continuous bioprocessing has emerged as one of the innovative approaches for manufacturing therapies cost-effectively and on a relatively small scale, offering multiple advantages.
Key Findings in the Global Continuous Bioprocessing Market Study:
In 2020, the filtration systems and consumables segment accounted for the largest share of the market
Based on product, the continuous bioprocessing market is segmented into filtration systems & consumables; chromatography systems & consumables; bioreactors; sterilizers; centrifuges; incubators & shakers; mixing systems; cell culture media, buffers, and reagents; and other products. The growing demand for higher standards of filter operations in biopharma manufacturing is one of the major drivers for the growth of this segment. Filter manufacturers are developing filtration technologies for continuous bioprocessing to achieve both separation and purification through a combination of physical removal capabilities of filtration and size exclusion.
The research & development segment is projected to grow at the highest CAGR during the forecast period
Based on application, the continuous bioprocessing market is segmented into commercial and R&D. The rising focus of R&D to develop vaccines and suitable therapies for COVID-19 and growing relevance of mAb manufacturing for the treatment of various diseases are driving the market growth. The R&D in cell and gene therapy is also accelerated, with over 900 candidates in clinical studies. Facility expansions of CROs or CDMOs to advance research in these areas are expected to boost market growth.
In 2020, the pharmaceutical and biotechnology companies segment dominated the global continuous bioprocessing market
Based on end user, the continuous bioprocessing market is segmented into pharmaceutical and biotechnology companies, CDMOs & CMOs, and academic and research institutes. Pharma and biopharma manufacturers are shifting from batch to continuous processing. This process provides considerable benefits to manufacturers by being more cost-effective, requiring less infrastructure, less space, less investment, less staff, all while manufacturing products in the same or perhaps less time than traditional batch methods.
Asia-Pacific: Fastest growing regional market
Based on region, the market is segmented into North America, Europe, APAC, Latin America, and the Middle East & Africa. The gradually emerging landscape of biopharmaceuticals in Asian countries, CDMO expansions, developments in bioprocessing technologies and partnerships, and collaborations among market players for biopharma manufacturing drives the market growth in Asia-Pacific.
Key Players
The report includes a competitive landscape based on an extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past three years. The key players profiled in the global continuous bioprocessing market report are 3M (U.S.), Cytiva (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Repligen Corporation (U.S.), Eppendorf AG (Germany), Applikon Biotechnology (Netherlands), Pall Corporation (U.S.), and Bionet (Spain).
Scope of the Report:
Continuous Bioprocessing Market, by Product
- Filtration Systems and Consumables
- Chromatography Systems and Consumables
- Bioreactors
- Sterilizers
- Centrifuges
- Incubators and Shakers
- Mixing Systems
- Cell Culture Media, Buffers, and Reagents
- Other instruments and consumables
Continuous Bioprocessing Market, by Application
- Commercial
- Vaccines
- mAb production
- Recombinant Protein Production
- Cell and Gene Therapy Production
- R&D
Continuous Bioprocessing Market, by End User
- Pharmaceutical and Biotechnology Companies
- Contract Development and Manufacturing Organizations and Contract Research Organizations
- Academic and Research Institutes
Continuous Bioprocessing Market, by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
Key questions answered in the report:
The global continuous bioprocessing market covers the market size & forecasts of continuous bioprocessing products like filtration systems & consumables; chromatography systems & consumables; bioreactors; sterilizers; centrifuges; incubators/shakers; mixing systems and cell culture media, reagents, and buffers; and other instruments and consumables.
The global continuous bioprocessing market is projected to reach $429.12 million by 2028, at a CAGR of 23.0% during the forecast period.
Based on product, the filtration systems and consumables commanded the largest share of the market in 2020.
Based on application, the continuous bioprocessing market is segmented into commercial and R&D. The R&D segment is expected to grow at the highest CAGR.
In 2020, the pharmaceutical and biotechnology companies segment accounted for the largest share of the market.
Some of the major factors driving the growth of this market include the growing demand for biopharmaceuticals, technological developments in continuous bioprocessing, product launches in the area of continuous bioprocessing, and global initiatives supporting the adoption of biopharmaceuticals. The growing shift towards the bioprocess 4.0 industry, growing opportunities in developing countries, and rising preference for personalized medicine are expected to create significant market growth opportunities.
The key players profiled in the global continuous bioprocessing market are 3M (U.S.), Cytiva (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Repligen Corporation (U.S.), Eppendorf AG (Germany), Applikon Biotechnology (Netherlands), Pall Corporation (U.S.), and Bionet (Spain)
Emerging economies like China and India are projected to offer significant growth opportunities for vendors in this market.
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-Up Approach
2.3.1.2. Top-Down Approach
2.3.1.3. Growth Forecast
2.4. Assumptions for the Study
2.5. Limitations for the Study
3. Executive Summary
4. Market Insights
4.1. Introduction
4.2. Drivers
4.2.1. The Gradual Adoption of Continuous Manufacturing
4.2.2. Recent Product Launches and Advances in the Continuous Bioprocessing Space
4.2.3. Global Initiatives Supporting the Adoption of Biopharmaceuticals
4.3. Restraint
4.3.1. The Limitations of Continuous Bioprocessing
4.4. Opportunities
4.4.1. The Shift Towards Bioprocessing 4.0
4.4.2. Untapped Markets in Developing Countries
4.4.3. The Rising Adoption of Personalized Medicines
4.5. Challenges
4.5.1. Manufacturers’ Reluctance to Shift from Batch Manufacturing to Continuous Manufacturing
4.6. Market Trends
4.6.1. Growth in the Use of Single-Use Technologies in Bioprocessing
4.7. Covid-19 Impact Analysis
5. Global Continuous Bioprocessing Market, By Product
5.1. Introduction
5.2. Filtration Systems and Consumables
5.3. Chromatography Systems and Consumables
5.4. Cell Culture Media, Buffers, and Reagents
5.5. Incubators and Shakers
5.6. Bioreactors
5.7. Centrifuges
5.8. Sterilizers
5.9. Other Instruments and Consumables
6. Global Continuous Bioprocessing Market, By Application
6.1. Introduction
6.2. Commercial Applications
6.2.1. Monoclonal Antibodies (mAb) Production
6.2.2. Cell and Gene therapy Production
6.2.3. Vaccine Manufacturing
6.2.4. Plasma Fractionation
6.2.5. Recombinant Protein Production
6.3. Research & Development (R&D)
7. Global Continuous Bioprocessing Market, By End User
7.1. Introduction
7.2. Pharmaceutical and Biotechnology Companies
7.3. Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs)
7.4. Academic and Research Institutes
8. Continuous Bioprocessing Market, By Geography
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. U.K
8.3.3. France
8.3.4. Spain
8.3.5. Italy
8.3.6. Rest of Europe (RoE)
8.4. Asia-Pacific
8.4.1. China
8.4.2. India
8.4.3. Japan
8.4.4. Rest of Asia-Pacific (RoAPAC)
8.5. Latin America
8.6. Middle East & Africa
9. Competitive Landscape
9.1. Introduction
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
10. Company Profiles (Business Overview, Product Portfolio, Financial Overview, and Strategic Developments)
10.1. 3M
10.2. Thermo Fisher Scientific, Inc.
10.3. Sartorious AG
10.4. Eppendorf AG
10.5. Pall Corporation
10.6. Cytiva
10.7. Merck KGaA
10.8. Repligen
10.9. Applikon Biotechnology
10.10. Bionet
11. Appendix
11.1. Questionnaire
11.2. Available Customization
LIST OF TABLES
Table 1 Global Continuous Bioprocessing Market Drivers: Impact Analysis (2021–2028)
Table 2 Global Continuous Bioprocessing Market Restraints: Impact Analysis (2021—2028)
Table 3 Global Continuous Bioprocessing Market Size, By Product, 2019–2028 (USD Million)
Table 4 Some of the Key Players offering Filtration Systems and Consumables for Continuous Bioprocessing
Table 5 Filtration Systems and Consumables Market Size, By Country/Region, 2019–2028 (USD Million)
Table 6 Some of the Key Players offering Chromatography Systems and Consumables for Continuous Bioprocessing
Table 7 Chromatography Systems and Consumables Market Size, By Country/Region, 2019–2028 (USD Million)
Table 8 Some of the Key Players offering Cell Culture Media, Buffers, and Reagents for Continuous Bioprocessing
Table 9 Cell Culture Media, Buffers, and Reagents Market Size, By Country/Region, 2019–2028 (USD Million)
Table 10 Some of the Key Players offering Incubators and Shakers for Continuous Bioprocessing
Table 11 Incubators and Shakers Market Size, By Country/Region, 2019–2028, (USD Million)
Table 12 Some of the Key Players offering Bioreactors for Continuous Bioprocessing
Table 13 Bioreactors Market Size, By Country/Region, 2019–2028 (USD Million)
Table 14 Some of the Key Players offering Centrifuges for Continuous Bioprocessing
Table 15 Centrifuges Market Size, By Country/Region, 2019–2028 (USD Million)
Table 16 Some of the Key Players offering Sterilizers for Continuous Bioprocessing
Table 17 Sterilizers Market Size, By Country/Region, 2019–2028 (USD Million)
Table 18 Some of the Key Players offering Other Instruments and Consumables for Continuous Bioprocessing
Table 19 Other Instruments and Consumables Market Size, By Country/Region, 2019–2028 (USD Million)
Table 20 Global Continuous Bioprocessing Market Size, By Application, 2019–2028, (USD Million)
Table 21 Global Continuous Bioprocessing Market Size for Commercial Applications, By Type, 2019–2028 (USD Million)
Table 22 Continuous Bioprocessing Market Size for Commercial Applications, By Country/Region, 2019–2028 (USD Million)
Table 23 Continuous Bioprocessing Market Size for Mab Production, By Country/Region, 2019–2028 (USD Million)
Table 24 Continuous Bioprocessing Market Size for Cell and Gene therapy Production, By Country/Region, 2019–2028 (USD Million)
Table 25 Continuous Bioprocessing Market Size for Vaccine Manufacturing, By Country/Region, 2019–2028 (USD Million)
Table 26 Continuous Bioprocessing Market Size for Plasma Fractionation, By Country/Region, 2019–2028 (USD Million)
Table 27 Continuous Bioprocessing Market Size for Recombinant Protein Production, By Country/Region, 2019–2028 (USD Million)
Table 28 Continuous Bioprocessing Market Size for R&D, By Country/Region, 2019–2028 (USD Million)
Table 29 Global Continuous Bioprocessing Market Size, By End User, 2019―2028, (USD Million)
Table 30 Continuous Bioprocessing Market for Pharmaceutical and Biotechnology Companies, By Country/Region, 2019―2028 (USD Million)
Table 31 Continuous Bioprocessing Market for CDMOs and CROs, By Country/Region, 2019―2028 (USD Million)
Table 32 Continuous Bioprocessing Market for Academic and Research Institutes, By Country/Region, 2019―2028(USD Million)
Table 33 Global Continuous Bioprocessing Market Size, By Country/Region, 2019–2028, (USD Million)
Table 34 North America: Continuous Bioprocessing Market Size, By Country, 2019–2028, (USD Million)
Table 35 North America: Continuous Bioprocessing Market Size, By Product, 2019–2028, (USD Million)
Table 36 North America: Continuous Bioprocessing Market Size, By Application, 2019–2028 (USD Million)
Table 37 North America: Continuous Bioprocessing Market Size for Commercial Applications, By Type, 2019–2028 (USD Million)
Table 38 North America: Continuous Bioprocessing Market Size, By End User, 2019–2028 (USD Million)
Table 39 U.S.: Continuous Bioprocessing Market Size, By Product, 2019–2028 (USD Million)
Table 40 U.S: Continuous Bioprocessing Market Size, By Application, 2019–2028, (USD Million)
Table 41 U.S.: Continuous Bioprocessing Market Size for Commercial Applications, By Type, 2019–2028 (USD Million)
Table 42 U.S.: Continuous Bioprocessing Market Size, By End User, 2019–2028 (USD Million)
Table 43 Canada: Continuous Bioprocessing Market Size, By Product, 2019–2028, (USD Million)
Table 44 Canada: Continuous Bioprocessing Market Size, By Application, 2019–2028, (USD Million)
Table 45 Canada: Continuous Bioprocessing Market Size for Commercial Applications, By Type, 2019–2028 (USD Million)
Table 46 Canada: Continuous Bioprocessing Market Size, By End User, 2019–2028, (USD Million)
Table 47 Europe: Continuous Bioprocessing Market Size, By Country, 2019–2028, (USD Million)
Table 48 Europe: Continuous Bioprocessing Market Size, By Product, 2019–2028, (USD Million)
Table 49 Europe: Continuous Bioprocessing Market Size, By Application, 2019–2028, (USD Million)
Table 50 Europe: Continuous Bioprocessing Market Size for Commercial Applications, By Type, 2019–2028 (USD Million)
Table 51 Europe: Continuous Bioprocessing Market Size, By End User, 2019–2028, (USD Million)
Table 52 Germany: Continuous Bioprocessing Market Size, By Product, 2019–2028, (USD Million)
Table 53 Germany: Continuous Bioprocessing Market Size, By Application, 2019–2028, (USD Million)
Table 54 Germany: Continuous Bioprocessing Market Size for Commercial Applications, By Type, 2019–2028 (USD Million)
Table 55 Germany: Continuous Bioprocessing Market Size, By End User, 2019–2028, (USD Million)
Table 56 U.K.: Continuous Bioprocessing Market Size, By Product, 2019–2028 (USD Million)
Table 57 U.K.: Continuous Bioprocessing Market Size, By Application, 2019–2028 (USD Million)
Table 58 U.K.: Continuous Bioprocessing Market Size for Commercial Applications, By Type, 2019–2028 (USD Million)
Table 59 U.K.: Continuous Bioprocessing Market Size, By End User, 2019–2028 (USD Million)
Table 60 France: Continuous Bioprocessing Market Size, By Product, 2019–2028, (USD Million)
Table 61 France: Continuous Bioprocessing Market Size, By Application, 2019–2028, (USD Million)
Table 62 France: Continuous Bioprocessing Market Size for Commercial Applications, By Type, 2019–2028 (USD Million)
Table 63 France: Continuous Bioprocessing Market Size, By End User, 2019–2028, (USD Million)
Table 64 An Exhaustive List of Biosimilars Manufactured in Rheumatology and their Availability in Spain
Table 65 Spain: Continuous Bioprocessing Market Size, By Product, 2019–2028, (USD Million)
Table 66 Spain: Continuous Bioprocessing Market Size, By Application, 2019–2028, (USD Million)
Table 67 Spain: Continuous Bioprocessing Market Size for Commercial Applications, By Type, 2019–2028(USD Million)
Table 68 Spain: Continuous Bioprocessing Market Size, By End User, 2019–2028, (USD Million)
Table 69 Italy: Continuous Bioprocessing Market Size, By Product, 2019–2028, (USD Million)
Table 70 Italy: Continuous Bioprocessing Market Size, By Application, 2019–2028, (USD Million)
Table 71 Italy: Continuous Bioprocessing Market Size for Commercial Applications, By Type, 2019–2028 (USD Million)
Table 72 Italy: Continuous Bioprocessing Market Size, By End User, 2019–2028, (USD Million)
Table 73 Rest of Europe: Continuous Bioprocessing Market Size, By Product, 2019–2028, (USD Million)
Table 74 Rest of Europe: Continuous Bioprocessing Market Size, By Application, 2019–2028 (USD Million)
Table 75 Rest of Europe: Continuous Bioprocessing Market Size for Commercial Applications, By Type, 2019–2028 (USD Million)
Table 76 Rest of Europe: Continuous Bioprocessing Market Size, By End User, 2019–2028 (USD Million)
Table 77 Asia-Pacific: Continuous Bioprocessing Market Size, By Country, 2019–2028, (USD Million)
Table 78 Asia-Pacific: Continuous Bioprocessing Market Size, By Product, 2019–2028, (USD Million)
Table 79 Asia-Pacific: Continuous Bioprocessing Market Size, By Application, 2019–2028 (USD Million)
Table 80 Asia-Pacific: Continuous Bioprocessing Market Size for Commercial Applications, By Type, 2019–2028 (USD Million)
Table 81 Asia-Pacific: Continuous Bioprocessing Market Size, By End User, 2019–2028, (USD Million)
Table 82 China: Continuous Bioprocessing Market Size, By Product, 2019–2028, (USD Million)
Table 83 China: Continuous Bioprocessing Market Size, By Application, 2019–2028, (USD Million)
Table 84 China: Continuous Bioprocessing Market Size for Commercial Applications, By Type, 2019–2028 (USD Million)
Table 85 China: Continuous Bioprocessing Market Size, By End User, 2019–2028, (USD Million)
Table 86 India: Continuous Bioprocessing Market Size, By Product, 2019–2028 (USD Million)
Table 87 India: Continuous Bioprocessing Market Size, By Application, 2019–2028, (USD Million)
Table 88 India: Continuous Bioprocessing Market Size for Commercial Applications, By Type, 2019–2028 (USD Million)
Table 89 India: Continuous Bioprocessing Market Size, By End User, 2019–2028, (USD Million)
Table 90 Japan: Continuous Bioprocessing Market Size, By Product, 2019–2028, (USD Million)
Table 91 Japan: Continuous Bioprocessing Market Size, By Application, 2019–2028, (USD Million)
Table 92 Japan: Continuous Bioprocessing Market Size for Commercial Applications, By Type, 2019–2028 (USD Million)
Table 93 Japan: Continuous Bioprocessing Market Size, By End User, 2019–2028, (USD Million)
Table 94 Rest of Asia-Pacific: Continuous Bioprocessing Market Size, By Product, 2019–2028 (USD Million)
Table 95 Rest of Asia-Pacific: Continuous Bioprocessing Market Size, By Application, 2019–2028 (USD Million)
Table 96 Rest of Asia-Pacific: Continuous Bioprocessing Market Size for Commercial Applications, By Type, 2019–2028 (USD Million)
Table 97 Rest of Asia-Pacific: Continuous Bioprocessing Market Size, By End User, 2019–2028 (USD Million)
Table 98 Latin America: Continuous Bioprocessing Market Size, By Product, 2019–2028, (USD Million)
Table 99 Latin America: Continuous Bioprocessing Market Size, By Application, 2019–2028 (USD Million)
Table 100 Latin America: Continuous Bioprocessing Market Size for Commercial Applications, By Type, 2019–2028 (USD Million)
Table 101 Latin America: Continuous Bioprocessing Market Size, By End User, 2019–2028, (USD Million)
Table 102 Middle East & Africa: Continuous Bioprocessing Market Size, By Product, 2019–2028 (USD Million)
Table 103 Middle East & Africa: Continuous Bioprocessing Market Size, By Application, 2019–2028 (USD Million)
Table 104 Middle East & Africa: Continuous Bioprocessing Market Size for Commercial Applications, By Type, 2019–2028 (USD Million)
Table 105 Middle East & Africa: Continuous Bioprocessing Market Size, By End User, 2019–2028 (USD Million)
Table 106 Recent Developments, By Company, 2019—2021
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Size Estimation
Figure 7 Global Continuous Bioprocessing Market Size, By Product, 2021–2028,(USD Million)
Figure 8 Global Continuous Bioprocessing Market Size, By Application, 2021–2028, (USD Million)
Figure 9 Global Continuous Bioprocessing Market Size, By End User, 2021–2028, (USD Million)
Figure 10 Global Continuous Bioprocessing Market, By Region
Figure 11 Market Dynamics
Figure 12 Global Continuous Bioprocessing Market Size, By Product, 2021–2028, (USD Million)
Figure 13 Global Continuous Bioprocessing Market Size, By Application, 2021–2028, (USD Million)
Figure 14 Global Continuous Bioprocessing Market Size, By End User, 2021–2028, (USD Million)
Figure 15 Global Continuous Bioprocessing Market Size, By Geography, 2021–2028, (USD Million)
Figure 16 North America Snapshot: Continuous Bioprocessing Market
Figure 17 Europe Snapshot: Continuous Bioprocessing Market
Figure 18 Asia-Pacific Snapshot: Continuous Bioprocessing Market
Figure 19 Key Growth Strategies Adopted by Leading Players, 2019—2021
Figure 20 Competitive Benchmarking of Key Players in the Continuous Bioprocessing Market (Based on Product offerings)
Figure 21 Competitive Benchmarking of Key Players in the Continuous Bioprocessing Market (Based on Geographic Presence)
Figure 22 3M: Financial Overview, 2020
Figure 23 Thermo Fisher Scientific, Inc: Financial Overview, 2020
Figure 24 Sartorious AG: Financial Overview, 2020
Figure 25 Eppendorf AG: Financial Overview, 2020
Figure 26 Danaher Corporation: Financial Overview, 2020
Figure 27 General Electric Company: Financial Overview, 2019
Figure 28 Merck KGaA: Financial Overview, 2020
Figure 29 Repligen Corporation: Financial Overview, 2020
COVID-19
This report provides pre & post COVID-19 market estimates.
Related Reports
Empty Capsules Market- Global Opportunity Analysis And Industry Forecast (2022-2029)
Published Date: Sep-2022
Pharmaceutical Packaging Market - Global Opportunity Analysis And Industry Forecast (2022-2029)
Published Date: Jun-2022
